Gamida completes enrolment in Phase I/II study of NiCord
The study enrolled 11 patients to evaluate NiCord as an alternative investigational treatment for HM and is expected to provide the results within six months. Gamida Cell research
Vertex has signed a definitive agreement to purchase Crinetics Pharmaceuticals in a transaction valued at nearly $10bn, or $8.8bn net of estimated cash acquired.
Simponi subcutaneous injection is indicated for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Janssen Biotech discovered and developed Simponi as a treatment for inflammatory autoimmune diseases involving TNF